<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737188</url>
  </required_header>
  <id_info>
    <org_study_id>IDT-1722-IU</org_study_id>
    <nct_id>NCT03737188</nct_id>
  </id_info>
  <brief_title>Institut Fuer Diabetes-Technologie Surveillance Program</brief_title>
  <official_title>Institut Fuer Diabetes-Technologie Surveillance Program for Blood Glucose Monitoring Systems in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the system accuracy of different blood glucose monitoring systems available in
      Europe
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A variety of blood glucose monitoring systems (BGMS) are available on the European market.
      For many of these BGMS, the system accuracy is unknown or it has not yet been assessed in
      manufacturer-independent studies. The IDT surveillance program aims at assessing the system
      accuracy of different BGMS that are available in Europe in a manufacturer-independent,
      investigator-initiated study. The initial study will cover 18 BGMS from 18 different
      manufacturers. Per BGMS, one test strip lot will be assessed based on procedures stated in
      the international standard ISO 15197:2013 / EN ISO 15197:2015.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">December 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of system accuracy based on ISO 15197</measure>
    <time_frame>For each subject, the experimental phase has an expected duration of up to 6 hours</time_frame>
    <description>Assessment of the analytical measurement performance of 18 blood glucose montoring systems based on procedures defined in ISO 15197</description>
  </primary_outcome>
  <enrollment type="Actual">126</enrollment>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood glucose monitoring systems for self-testing</intervention_name>
    <description>Capillary blood samples will be used for the evaluation of system accuracy.</description>
    <other_name>18 BGMS from 18 different manufacturers: ABRA, Accu-Chek Guide, AURUM Blutzucker-Messsystem, CareSens Dual, CERA-CHEK 1 Code, Contour next ONE, eBsensor, FreeStyle Freedom Lite, GL 50 (evo)</other_name>
    <other_name>GlucoCheck GOLD, GlucoMen areo 2K, GluNEO, MyStar DoseCoach, OneTouch Verio Flex, Pic GlucoTest, Rightest GM700S, TRUEyou Blutzuckermesssystem, WaveSense JAZZ WIRELESS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, with type 1 diabetes, type 2 diabetes or subjects without diabetes

          -  Signed informed consent form

          -  Minimum age of 18 years

          -  ubjects are legally competent and capable to understand character, meaning and
             consequences of the study.

          -  If blood glucose values &lt; 80 mg/dl or &gt; 300 mg/dl shall be measured after short term
             alteration in insulin therapy:

          -  Male or female with type 1 diabetes and intensified insulin therapy or insulin pump
             therapy.

          -  Signature of subjects to document consent with these procedures on informed consent
             form.

        Exclusion Criteria:

          -  Pregnancy or lactation period

          -  Severe acute disease (at the study physician's discretion)

          -  Severe chronic disease with potential risk during the test procedures (at the study
             physician's discretion)

          -  Current constitution that compromises the subject's capability to participate in the
             study (at the study physician's discretion)

          -  Being unable to give informed consent

          -  &lt; 18 years

          -  Legally incompetent

          -  Being committed to an institution (e.g. psychiatric clinic)

          -  Language barriers potentially compromising an adequate compliance with study
             procedures

          -  Dependent on investigator or sponsor

          -  If blood glucose values &lt; 80 mg/dl shall be measured after short term alteration in
             insulin therapy, subjects with type 1 diabetes, suffering from:

          -  Coronary heart disease

          -  Condition after myocardial infarction

          -  Condition after cerebral events

          -  Peripheral arterial occlusive disease

          -  Hypoglycemia unawareness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft an der Universität Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

